Cargando…

Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B

BACKGROUND: Hepatitis B virus (HBV) infection is a serious public health problem worldwide. This study aimed to investigate the relationship between serum alpha-fetoprotein (AFP) levels and pathological stages of liver biopsy in patients with chronic hepatitis B (CHB). METHODS: The study included 61...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu-rui, Lin, Bin-bin, Zeng, Da-wu, Zhu, Yue-yong, Chen, Jing, Zheng, Qi, Dong, Jing, Jiang, Jia-ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139492/
https://www.ncbi.nlm.nih.gov/pubmed/25128299
http://dx.doi.org/10.1186/1471-230X-14-145
_version_ 1782331367394115584
author Liu, Yu-rui
Lin, Bin-bin
Zeng, Da-wu
Zhu, Yue-yong
Chen, Jing
Zheng, Qi
Dong, Jing
Jiang, Jia-ji
author_facet Liu, Yu-rui
Lin, Bin-bin
Zeng, Da-wu
Zhu, Yue-yong
Chen, Jing
Zheng, Qi
Dong, Jing
Jiang, Jia-ji
author_sort Liu, Yu-rui
collection PubMed
description BACKGROUND: Hepatitis B virus (HBV) infection is a serious public health problem worldwide. This study aimed to investigate the relationship between serum alpha-fetoprotein (AFP) levels and pathological stages of liver biopsy in patients with chronic hepatitis B (CHB). METHODS: The study included 619 patients who were diagnosed with CHB from March 2005 to December 2011. AFP levels were measured by electrochemiluminescence. Liver biopsy samples were classified into five levels of inflammation (G) and fibrosis (S) stages, according to the Chinese guidelines for prevention and treatment of viral hepatitis. Two multivariable ordinal regression models were performed to determine associations between AFP, GGT, and APRI (AST/PLT ratio) and stages of inflammation and fibrosis. RESULTS: Significant positive and moderate correlations were shown between AFP levels and inflammation stages and between AFP levels and fibrosis stages (ρ = 0.436 and 0.404, p < 0.001). Median values of AFP at liver fibrosis stages S0-1, S2, S3, and S4 were 3.0, 3.4, 5.4, and 11.3 ng/ml, respectively, and median APRI (AST/PLT ratio) was 0.41. Receiver operating characteristic (ROC) curve analyses revealed that the areas under the curves (AUCs) were 0.685, 0.727, and 0.755 (all p <0.001) for judging inflammation stages of G ≥ 2, G ≥ 3, G = 4 by AFP; and 0.691, 0.717, and 0.718 (all p <0.001) for judging fibrosis stages of S ≥ 2, S ≥ 3, and S = 4 by AFP. APRI levels showed significant positive and moderate correlations with inflammation stages (ρ = 0.445, p < 0.001). AST, GGT, and APRI levels showed significant positive but very weak to weak correlations with fibrosis stages (ρ = 0.137, 0.237, 0.281, p < 0.001). CONCLUSIONS: Serum AFP levels increased as pathological levels of inflammation and fibrosis increased in CHB patients. Our data showed the clinical significance of serum AFP levels in diagnosing liver inflammation and fibrosis. Assessment of liver pathology may be improved by creating a predictive mathematical model by which AFP levels with other biomarkers.
format Online
Article
Text
id pubmed-4139492
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41394922014-08-22 Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B Liu, Yu-rui Lin, Bin-bin Zeng, Da-wu Zhu, Yue-yong Chen, Jing Zheng, Qi Dong, Jing Jiang, Jia-ji BMC Gastroenterol Research Article BACKGROUND: Hepatitis B virus (HBV) infection is a serious public health problem worldwide. This study aimed to investigate the relationship between serum alpha-fetoprotein (AFP) levels and pathological stages of liver biopsy in patients with chronic hepatitis B (CHB). METHODS: The study included 619 patients who were diagnosed with CHB from March 2005 to December 2011. AFP levels were measured by electrochemiluminescence. Liver biopsy samples were classified into five levels of inflammation (G) and fibrosis (S) stages, according to the Chinese guidelines for prevention and treatment of viral hepatitis. Two multivariable ordinal regression models were performed to determine associations between AFP, GGT, and APRI (AST/PLT ratio) and stages of inflammation and fibrosis. RESULTS: Significant positive and moderate correlations were shown between AFP levels and inflammation stages and between AFP levels and fibrosis stages (ρ = 0.436 and 0.404, p < 0.001). Median values of AFP at liver fibrosis stages S0-1, S2, S3, and S4 were 3.0, 3.4, 5.4, and 11.3 ng/ml, respectively, and median APRI (AST/PLT ratio) was 0.41. Receiver operating characteristic (ROC) curve analyses revealed that the areas under the curves (AUCs) were 0.685, 0.727, and 0.755 (all p <0.001) for judging inflammation stages of G ≥ 2, G ≥ 3, G = 4 by AFP; and 0.691, 0.717, and 0.718 (all p <0.001) for judging fibrosis stages of S ≥ 2, S ≥ 3, and S = 4 by AFP. APRI levels showed significant positive and moderate correlations with inflammation stages (ρ = 0.445, p < 0.001). AST, GGT, and APRI levels showed significant positive but very weak to weak correlations with fibrosis stages (ρ = 0.137, 0.237, 0.281, p < 0.001). CONCLUSIONS: Serum AFP levels increased as pathological levels of inflammation and fibrosis increased in CHB patients. Our data showed the clinical significance of serum AFP levels in diagnosing liver inflammation and fibrosis. Assessment of liver pathology may be improved by creating a predictive mathematical model by which AFP levels with other biomarkers. BioMed Central 2014-08-16 /pmc/articles/PMC4139492/ /pubmed/25128299 http://dx.doi.org/10.1186/1471-230X-14-145 Text en Copyright © 2014 Liu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research Article
Liu, Yu-rui
Lin, Bin-bin
Zeng, Da-wu
Zhu, Yue-yong
Chen, Jing
Zheng, Qi
Dong, Jing
Jiang, Jia-ji
Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B
title Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B
title_full Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B
title_fullStr Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B
title_full_unstemmed Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B
title_short Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B
title_sort alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis b
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139492/
https://www.ncbi.nlm.nih.gov/pubmed/25128299
http://dx.doi.org/10.1186/1471-230X-14-145
work_keys_str_mv AT liuyurui alphafetoproteinlevelasabiomarkerofliverfibrosisstatusacrosssectionalstudyof619consecutivepatientswithchronichepatitisb
AT linbinbin alphafetoproteinlevelasabiomarkerofliverfibrosisstatusacrosssectionalstudyof619consecutivepatientswithchronichepatitisb
AT zengdawu alphafetoproteinlevelasabiomarkerofliverfibrosisstatusacrosssectionalstudyof619consecutivepatientswithchronichepatitisb
AT zhuyueyong alphafetoproteinlevelasabiomarkerofliverfibrosisstatusacrosssectionalstudyof619consecutivepatientswithchronichepatitisb
AT chenjing alphafetoproteinlevelasabiomarkerofliverfibrosisstatusacrosssectionalstudyof619consecutivepatientswithchronichepatitisb
AT zhengqi alphafetoproteinlevelasabiomarkerofliverfibrosisstatusacrosssectionalstudyof619consecutivepatientswithchronichepatitisb
AT dongjing alphafetoproteinlevelasabiomarkerofliverfibrosisstatusacrosssectionalstudyof619consecutivepatientswithchronichepatitisb
AT jiangjiaji alphafetoproteinlevelasabiomarkerofliverfibrosisstatusacrosssectionalstudyof619consecutivepatientswithchronichepatitisb